Status:
TERMINATED
Extension Study Of Tanezumab In Osteoarthritis
Lead Sponsor:
Pfizer
Conditions:
Osteoarthritis
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
Detailed Description
This study was terminated on 27 October 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential...
Eligibility Criteria
Inclusion
- Must have participated in previous (specific) Phase 3 trials of Tanezumab in osteoarthritis
Exclusion
- Willing to comply with scheduled visits and treatment plan Is medically fit to participate in the trial in the judgement of the Investigator
Key Trial Info
Start Date :
February 6 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 23 2011
Estimated Enrollment :
2147 Patients enrolled
Trial Details
Trial ID
NCT00809783
Start Date
February 6 2009
End Date
June 23 2011
Last Update
May 10 2021
Active Locations (226)
Enter a location and click search to find clinical trials sorted by distance.
1
Pinncale Research Group, LLC
Anniston, Alabama, United States, 36201
2
Anniston Medical Clinic, PC
Anniston, Alabama, United States, 36207
3
Pinnacle Research Group, LLC
Anniston, Alabama, United States, 36207
4
Greystone Medical Center
Birmingham, Alabama, United States, 35242